• Enabling

    Enabling

    Knowledge, Skills and Big Data

  • Innovation and Creation

    Innovation and Creation

    Open Mindset and Think Disruptive

  • Planning Forward

    Planning Forward

    Focus, Ensuring Performance and Success

  • Growth and Sustainability

    Growth and Sustainability

    Assuring Shareholder Values and Returns

  • Staff and Family

    Staff and Family

    High Impact Performance and Quality Life

  • Corporate Social Responsibilities

    Corporate Social Responsibilities

    Living Harmoniously with Nature and Communities

EPP3: Orthopaedic devices - Sima Medical



Sima Medical will be championing an effort to develop orthopaedic clinical devices in Malaysia via its joint venture with the Naton Medical Group of China and Malaysian partners.
  • Investment by 2020 (million)
    RM7.7
  • GNI Impact by 2020 (million)
    RM131.8
  • Jobs created by 2020
    100
The OEM will be based in Malaysia with the technologies and intellectual properties provided by the Naton Medical Group. Sima Medical will focus on the following orthopaedic product segments:

- Nail, Plate, Knee, Hip, Spine, Dental and Cranio-Maxillofacial systems
   
The manufacturing of these segments will be outsourced by Sima Medical to Straits Orthopaedics and/or ABio Orthopaedics of Penang. Sima Medical will directly undertake the marketing and sales of products to emerging and international markets in Penang and the R&D will be based in Petaling Jaya.

Market sector especially in the Asia Pacific are achieving double digits growth in orthopaedics field.

Therefore, Malaysia is an ideal location for Sima Medical for two main reasons include internationally cost competitive and positive perception of the Malaysian made products. The projected timelines for this project are as per below:
  • Phase 1 – launch products into the Malaysian market before the end of 2014
  • Phase 2 – launch products into the Asia Pacific markets before the end of 2015
 Source: ETP website


Read more

EPP3: Investment in Sterile Injectables/Infusions by Kotra Pharma



Kotra Pharma will be investing RM60 million to develop a manufacturing line to produce sterile injectable or infusion products. These products are currently not produced in Malaysia and it will be a pioneering initiative.
  • Investment by 2020 (million)
    RM60
  • GNI Impact by 2020 (million)
    RM35.2
  • Jobs created by 2020
    99
The manufacturing line will be an addition to the world class pharmaceutical plant worth RM152 million which was initiated in 2010.

Kotra will be able to supply the Ministry of Health through this investment which will then substitute the need to import these products. Kotra currently exports to over 40 countries to date and is looking to expand the product range in its export market.

Source: ETP website
 


Read more

EPP3 - pMDI by RBL



From the ETP website, RB Lifescience Sdn Bhd (RBL), will be building a pharmaceutical plant for the production of generic pMDI inhalers and oncology injectables.

The commercial production of these medicines will kick start in 2016 and the later in 2017. This initiative has large potential as it has an expected growth rate of 8-10% pa in Malaysia and in the ASEAN region.
  • Investment by 2020 (million)
    RM94.5
  • GNI Impact by 2020 (million)
    RM109.7
  • Jobs created by 2020
    152
The generic medicines and the technology are new and currently unavailable in this region. Therefore, RBL will acquire new technology via technology transfer agreements with renowned international pharmaceutical companies. Through this, RBL aims to develop the nation’s pharmaceutical sector by becoming a large exporter of these generic medicines by 2020.

Currently, inhalers and oncology injectables are imported by the countries in the ASEAN region. 

Source: ETP website Project 29-08-2013

 


Read more

Caring Pharmacy’s IPO oversubscribed 33.66 times



Caring Pharmacy Group Bhd’s offer of 10.87 million shares of RM1.25 each to the public was oversubscribed by 33.66 times.

The community pharmacy operator, which is seeking a listing on the Main Market of Bursa Malaysia on Nov 13, said there were 20,137 applications valued at RM471.64mil from the public.

Caring managing director Chong Yeow Siang said the overwhelming response reflected the healthy fundamentals and the potential growth prospects.

The joint placement agents also confirmed the 14.20 million shares made available for private placement were oversubscribed, according to a statement issued on Saturday.

The listing exercise involved the public issuance of 35 million new shares, which would result in raising  RM43.75mil.

Caring said 41% of the proceeds would be used to open new pharmacy outlets and another 27% for working capital.

Kenanga Investment Bank Bhd is the principal adviser, managing underwriter, joint underwriter with MIDF Amanah Investment Bank Bhd, and joint placement agent with Inter-Pacific Securities Sdn Bhd.
Source: theSTAR 02-11-2013


Read more

CCM Duopharma, Korea’s PanGen: Phaes III -Epoetin-Alfa



CCM Duopharma Biotech Bhd (CCMD) and South Korea’s PanGen Biotech will conduct phase three clinical trials of the latter’s PDA10 drug to treat patients with anemia due to chronic kidney failure.

CCMD said on Friday if the trials, starting in November are successful, it will have the commercialisation rights to market and distribute the drug in Malaysia, Singapore and Brunei, worth more than RM50mil annually.

 

PDA10, or Epoetin-Alfa, is PanGen’s first commercial finished "biosimilar" – that is, a follow-on version of existing bio-pharmaceutical product whose patent has expired.

The clinical trial costing RM8mil involves 18 sites and 300 patients in Malaysia, while in Korea, where testing is already underway, it includes five sites and 40 patients.

To recap, the trial follows the joint clinical trial agreement with PanGen in June 2012. The trial will conform with the European Medicines Agency and the Malaysian National Pharmaceutical Control Bureau (NPCB) guidelines.

“This agreement will enable CCMD and CCM Group to compete for high value added partnership projects in the commercialisation of biosimilars while eliminating the need to invest in very expensive clinical trials and long gestation periods to deliver the product to market,” said Amirul Feisal, a CCMD board member.

Biosimilars, dominated by global pharmaceutical players, is forecast to expand at a compounded average growth rate of 12% in Asia, and is expected to be worth an estimated RM8bil in Southeast Asia by 2020.

CCMD invested RM7mil to establish Malaysia’s first NPCB-certified GMP Biological Fill and Finish facility in Klang and it might invest an additional RM9mil for a pre-filled syringe suite should the phase three trials prove successful.
Source: theSTAR 01-11-2013


Read more

Malaysia: Average Salary increase of 5.7% in 2014



Malaysian employees are expected to see an average salary increase of 5.7% in 2014, higher than the national average salary increase of 5.3% this year, given the good growth prospects for local businesses going forward, according to a latest survey by Towers Watson.

Findings of the "2013 General Industry Total Rewards Survey – Malaysia" also found that employee turnover rate in the general industry in Malaysia has increased to 13.2% in 2013 from 12.3% last year."Manufacturing, conglomerates and financial services industries were experiencing high staff turnover, with manufacturing experiencing 24% employee churn, conglomerates at 14%, business process outsourcing at 19% and financial services at 13.3% this year," said Towers Watson in a statement yesterday, 30th October 2013

It attributed a key reason for the higher turnover rate in the Malaysian general industry to employees feeling that the economy will remain stable despite the uncertain global climate. "Another reason is that local organisations are also actively taking steps to improve their employee value proposition to attract top talent besides offering higher salaries and faster growth opportunities" said Towers Watson global data services practice leader for Southeast Asia, Sean Darilay in a statement yesterday.

He said an earlier Towers Watson's "2012 Global Workforce Study" revealed that 51% of Malaysian employees felt that they have to switch to another organisation to advance in their career or to achieve higher job level, with an "alarming" 83% of them willing to relocate to achieve this. "It is unsurprising that career development is a priority for employees in Malaysia where growth prospects are brighter. As the working class population expands, many young workers are demonstrating a strong desire to build a successful career in line with their aspirations to achieve a better quality of life," Darilay said.

"Employers should also recognise that while pay is still an important element in the equation, the key is to be able to design a comprehensive employee value proposition that balances different drivers and motivators of performance," he added.

Entry level salaries for fresh graduates increased by 8% in 2013 and ranges between RM2,400 and RM2,800 per month. In comparison to this, entry level salaries for MBA graduates range between RM2,600 and RM3,000 per month.

 The survey findings noted that positions in sales, information technology, finance, marketing and customer services/technical support remained as hot jobs. "This is due to the continuous need for organisations to strengthen their brand, improve sales leading to improved ROI and reduce operations costs by improving technology efficiency and productivity," Darilay said.

The "2013 General Industry Total Rewards Survey – Malaysia" saw over 350 organisations from across industries in Malaysia participating. It is an annual survey that provides insights into current compensation practises and trends in Malaysia, thereby aiding organisations to make informed decisions with respect to their total reward programmes.
Source: theSun 31-10-2013
 



Read more

Expats rank Malaysia among best countries to work in



Under the Expat Economics section, the HSBC Expat Explorer Survey 2013, published recently, ranked Malaysia 14th out of a league table of 37 countries, commending its young and dynamic population and a growing economy. The HSBC Explorer Expat Survey 2013 compiled findings from about 7,000 expats worldwide.

Expatriates ranked Malaysia as one of the better places in the world to work in, with Malaysian work culture ranked second in the world, and Malaysians considered the fourth easiest country in which to make friends.

It ranked Malaysia 5th in the world in terms of household income, and 11th where expat satisfaction with the local economy was concerned. The country however fared poorly at 27th in terms of disposable income.

It said that expats were also "upbeat" about Malaysia's local economy, with 41% of them here believing that it was getting better, and that nearly eight in ten expats here were also satisfied with the local economy.

"As a result, few expats are looking to leave the country because of a negative economic outlook, only 15% compared to a global average of 25%," the study said.

The survey however ranked Malaysia's neighbours Thailand, Indonesia and Singapore better in terms of expat-related economics, ranking them 4th, 6th and 9th respectively.

Expats also seemed to be less taken with Malaysia as a second home. The country ranked 20th under the survey's Expat Experience list, behind Thailand and Singapore, which ranked 1st and 6th in the world respectively.

Expats, according to the survey's website, found it easy to make friends here (4th), though integrating into the community was another matter (27th). Organising healthcare was not a problem (5th) for expats, but access to quality healthcare was an issue (29th).

In terms of local work culture, the survey found Malaysia near the top at 2nd, though expats seemed to feel less welcome at work (32nd) than in other countries. A work/life balance was also a problem, with Malaysia at 31st on the list.

Learning and using the local language was also a challenge for expats here, with Malaysia ranking at 23rd and 29th respectively.

Malaysian food was also not seen in a good light. To expats, local cuisine was considered unhealthy (35th). Getting used to it was an issue (31st), and enjoying it appeared to be a problem (34th).

Many expats here however seemed to have a great social life (2nd) and tended to be very sporty (2nd). Also, 54% expats surveyed here believed that Malaysia had a higher quality of life, as opposed to a global average of 45%.

Malaysia could not be ranked under the survey's full list, included in the Expat Survey league table as there was not enough data over the raising of expat children.


Read more